Is ADPT a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Adaptive Biotechnologies (ADPT) rests on clonoSEQ MRD volume and reimbursement: The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. Revenue (TTM) is ~$250M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. Whether ADPT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system. Its commercial engine is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test that measures how many cancer cells remain in a patient during and after treatment, used mainly in blood cancers such as multiple myeloma, ALL, and CLL. The MRD segment now contributes roughly 95 percent of revenue and includes both clinical testing and pharma partnerships that use the platform in drug trials. A second Immune Medicine arm pursues drug discovery and includes a long-running collaboration with Genentech on neoantigen-directed T-cell therapies. The investment picture is a diagnostics growth story reaching an inflection point. First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, MRD revenue grew about 53 percent, and clonoSEQ test volume climbed about 41 percent, prompting management to raise full-year MRD guidance toward roughly $260 million to $270 million. Losses have narrowed sharply and adjusted EBITDA is near breakeven, while a large cash balance funds the runway. In June 2026 the company announced a plan to separate the profitable, scaled MRD business from the earlier-stage Immune Medicine unit, a move that could reshape how the two pieces are valued.
What's the case for buying ADPT?
1. clonoSEQ MRD volume and reimbursement
The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. Expanding clinical guidelines, broader payer coverage, and adoption in additional blood-cancer indications support continued volume growth. Because MRD is roughly 95 percent of revenue, this is the metric that moves the story.
2. Pharma and biopharma partnerships
Beyond clinical testing, drugmakers use the MRD platform as a trial endpoint, and the company recognized milestone revenue tied to regulatory progress, including its first U.S. primary-endpoint milestone in early 2026. These partnerships add higher-margin, lumpier revenue on top of the recurring clinical test base. They also validate MRD as an accepted measure in oncology drug development.
3. Path to profitability
Net loss narrowed and adjusted EBITDA loss shrank toward breakeven in early 2026 as the MRD business scaled, a notable shift for a company that historically burned cash. Management has framed MRD as having reached profitability on a standalone basis. Continued operating leverage is central to the bull framing.
4. Planned MRD / Immune Medicine separation
In June 2026 the company announced plans to separate its scaled, profitable MRD business from the earlier-stage Immune Medicine unit, with a preferred path expected by year-end 2026. A split could let the market value a clean diagnostics grower on its own while isolating the drug-discovery risk. The structure and timing remain unsettled.
What are the risks to ADPT?
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.
How is ADPT valued? (as of July 2026)
Snapshot for ADPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$250M
- Q1 2026 revenue: ~$70.9M (up ~35% YoY)
- 2026 MRD revenue guidance: ~$260M to $270M
- Q1 2026 net loss: ~$20M (improved from ~$30M)
- Cash and investments: ~$237M
- Market cap: ~$3.6B
As of July 2026 ADPT trades at a high revenue multiple typical of a growing, near-breakeven diagnostics company rather than on earnings, since it remains unprofitable on a consolidated basis. The large cash balance relative to burn gives multi-year runway. Valuation hinges heavily on continued MRD volume growth and how the market treats a potential separation.
How do you decide if ADPT is a buy?
Rather than asking whether ADPT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ADPT indirectly through an index or sector ETF before adding more.
For the full picture, see the ADPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ADPT against your real portfolio and see your actual exposure before deciding.
The bottom line on ADPT
The bottom line: Adaptive Biotechnologies's story right now is clonoSEQ MRD volume and reimbursement, with revenue (ttm) at ~$250M. If you believe that narrative continues, the call is about sizing ADPT sensibly and checking overlap with what you own; if you doubt it (the risk: aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ADPT with Walnut
Use Adaptive Biotechnologies as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ADPT a good stock to buy right now?
+
The case for Adaptive Biotechnologies right now is clonoSEQ MRD volume and reimbursement, with revenue (ttm) at ~$250M. If you believe that thesis holds, ADPT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Adaptive Biotechnologies do?
+
Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system.
What are the main risks of ADPT?
+
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.
What does Adaptive Biotechnologies (ADPT) do?
+
It operates an immune-medicine platform that reads the genetics of the adaptive immune system. Its main commercial product is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test used to monitor remaining cancer cells, primarily in blood cancers. A separate arm pursues immune-based drug discovery.
What is clonoSEQ and why does it matter to ADPT?
+
clonoSEQ is Adaptive's MRD diagnostic that measures how many cancer cells remain during and after treatment. It drives roughly 95 percent of the company's revenue, so its test volume, reimbursement, and clinical adoption are the central factors in the business.
Is ADPT profitable?
+
As of July 2026 the company still reports a consolidated net loss, though it has narrowed sharply and adjusted EBITDA is near breakeven. Management has described the standalone MRD business as having reached profitability, while the broader company is not yet profitable.
How fast is ADPT growing?
+
First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, with MRD revenue up about 53 percent and clonoSEQ volume up about 41 percent. The company raised full-year MRD guidance toward roughly $260 million to $270 million.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ADPT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.